Migdal Insurance & Financial Holdings Ltd. decreased its position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) by 53.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,726 shares of the biopharmaceutical company’s stock after selling 211,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. owned 0.68% of Vascular Biogenics worth $1,133,000 at the end of the most recent reporting period.
Separately, KCG Holdings Inc. acquired a new stake in Vascular Biogenics during the first quarter valued at $248,000. 11.17% of the stock is owned by institutional investors and hedge funds.
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) traded up $0.25 during trading hours on Friday, hitting $7.65. The company’s stock had a trading volume of 224,200 shares, compared to its average volume of 306,084. Vascular Biogenics Ltd. has a 12 month low of $3.90 and a 12 month high of $7.70.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. sell-side analysts expect that Vascular Biogenics Ltd. will post -0.81 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/migdal-insurance-financial-holdings-ltd-trims-position-in-vascular-biogenics-ltd-vblt.html.
A number of brokerages have weighed in on VBLT. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Vascular Biogenics in a research report on Tuesday, November 7th. Chardan Capital boosted their price target on Vascular Biogenics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Finally, Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Vascular Biogenics has an average rating of “Buy” and an average target price of $16.00.
Vascular Biogenics Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.